Category Amyloidosis Treatment

9 Sep

TTR Stabilization in Cardiac Amyloidosis: How It Works & When It’s Used

Learn how TTR stabilizers such as tafamidis and acoramidis slow ATTR cardiac amyloidosis, how they work, what clinical trials show, and how stabilization differs from gene silencing.

9 Sep

Gene Silencers in Cardiac Amyloidosis: How They Work & When They’re Used

Learn how gene silencers reduce transthyretin production in ATTR cardiac amyloidosis, how vutrisiran works, what clinical trials show, and how these therapies differ from TTR stabilizers.

4 Sep

Pacemaker in Cardiac Amyloidosis: How It Works & When It’s Used

Learn how pacemakers are used in cardiac amyloidosis, when implantation may be needed, how the procedure works, and why pacing strategy and follow-up matter.

31 Aug

ICD Implantation in Cardiac Amyloidosis: How It Works & When It’s Used

Learn how implantable cardioverter-defibrillators (ICDs) work in cardiac amyloidosis, when they may be considered, how implantation is performed, and why patient selection is essential.

27 Aug

Device Therapy in Cardiac Amyloidosis: Pacemakers, ICDs and Cardiac Resynchronization Therapy

Learn how pacemakers, ICDs and cardiac resynchronization therapy (CRT) are used in cardiac amyloidosis, including their indications, potential benefits, limitations and the importance of individualized patient selection.

26 Aug

Liver Transplantation in Amyloidosis: When Is It Considered?

Liver transplantation was historically an important disease-modifying treatment for hereditary ATTR amyloidosis. Learn which patients may still be considered today, how genotype and cardiac involvement affect eligibility, why disease can progress after transplantation, and how modern TTR-directed therapies have changed its role.

We advance cardiac amyloidosis care across Africa through collaboration, training, and research. Join us to change the future of heart health and empower local clinicians with knowledge and tools.

LOG IN